Literature DB >> 7000458

Angiotensin and CNS regulation of blood pressure.

K L Barnes, C M Ferrario.   

Abstract

It appears that angiotensin II (AII) has access to the CNS by three routes: endogenous formation within the brain, passage into CSF, or transfer across "gaps" in the blood-brain barrier. The mode of access influences both the characteristics and the magnitude of the cardiovascular effects exerted by AII within the CNS. In the dog the effects of blood-borne AII on the area postrema (AP) in the IV ventricle seem to have the most physiological significance. In recent experiments we have characterized both the histological composition of this structure and its physiological effects. While electrical stimulation of the AP, in similarity to the pressor effects of intravertebral AII, produces a hypertensive response dependent on sympathetic vasomotor outflow, ablation of this structure results in mild hypotension associated with decreased hemodynamic variability and altered vascular responsiveness to intravenous AII and norepinephrine. Recent data suggest that the sympatho-facilitative action of AII on the AP may involve endogenous opiates in the brainstem.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000458     DOI: 10.3109/10641968009037125

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 0148-3927            Impact factor:   1.749


  3 in total

Review 1.  Comparative aspects of the area postrema: fine-structural considerations help to determine its function.

Authors:  R A Leslie
Journal:  Cell Mol Neurobiol       Date:  1986-06       Impact factor: 5.046

2.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

3.  Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system.

Authors:  Heinrich E Lob; Paul J Marvar; Tomasz J Guzik; Shraya Sharma; Louise A McCann; Cornelia Weyand; Frank J Gordon; David G Harrison
Journal:  Hypertension       Date:  2009-12-14       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.